User:Mr. Ibrahem/Rucaparib

Rucaparib, sold under the brand name Rubraca, is a medication used for ovarian cancer, fallopian tube cancer, peritoneal cancer, and prostate cancer. It is used after other treatments have failed. It is taken by mouth.

Common side effects include tiredness, nausea, kidney problems, liver problems, low red blood cells, abnormal taste, diarrhea, low platelets, and abdominal pain. Other side effects may include acute myeloid leukemia and low neutrophils. Use during pregnancy may harm the baby. It is a PARP inhibitor, which block DNA repair in cells with mutation in the BRCA gene.

Rucaparib was approved for medical use in the United States in 2016 and Europe in 2018. In the United States it costs about 9,100 USD per month as of 2021.